Related Experiment Video
Updated: Jun 22, 2025
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
Diverse Strategies for Modulating Insulin Resistance: Causal or Consequential Inference on Metabolic Parameters in
Eiji Kutoh1,2,3,4, Alexandra N Kuto1, Rumiko Okada4
1Biomedical Center, Tokyo 132-0034, Japan.
Abstract:
Bacground and Objectives: The objective of this study is to investigate how different therapies modulating insulin resistance, either causally or consequently, affect metabolic parameters in treatment-naïve subjects with T2DM. Subjects and Methods: A total of 212 subjects were assigned to receive either a tight Japanese diet (n = 65), pioglitazone at doses ranging from 15-30 mg/day (n = 70), or canagliflozin at doses ranging from 50-100 mg/day (n = 77) for a duration of three months. Correlations and changes (Δ) in metabolic parameters relative to insulin resistance were investigated. Results: Across these distinct therapeutic interventions, ΔHOMA-R exhibited significant correlations with ΔFBG and ΔHOMA-B, while demonstrating a negative correlation with baseline HOMA-R. However, other parameters such as ΔHbA1c, ΔBMI, ΔTC, ΔTG, Δnon-HDL-C, or ΔUA displayed varying patterns depending on the treatment regimens. Participants were stratified into two groups based on the median value of ΔHOMA-R: the lower half (X) and upper half (Y). Group X consistently demonstrated more pronounced reductions in FBG compared to Group Y across all treatments, while other parameters including HbA1c, HOMA-B, TC, TG, HDL-C, non-HDL-C, TG/HDL-C ratio, or UA exhibited distinct regulatory responses depending on the treatment administered. Conclusions: These findings suggest that (1) regression to the mean is observed in the changes in insulin resistance across these therapies and (2) the modulation of insulin resistance with these therapies, either causally or consequentially, results in differential effects on glycemic parameters, beta-cell function, specific lipids, body weight, or UA.
Insights
Different therapies for type 2 diabetes (T2DM) impact insulin resistance and metabolic markers differently. Regression to the mean was observed, with varying effects on glucose, lipids, and weight across interventions.
Area of Science:
- Metabolic diseases
- Endocrinology
- Pharmacology
Background:
- Insulin resistance is a key factor in type 2 diabetes mellitus (T2DM).
- Understanding how therapies targeting insulin resistance affect metabolic parameters is crucial for T2DM management.
- Treatment-naïve T2DM subjects offer a valuable cohort for studying initial therapeutic responses.
Purpose of the Study:
- To investigate the effects of distinct therapies on insulin resistance and metabolic parameters in treatment-naïve T2DM patients.
- To analyze correlations between changes in insulin resistance and other metabolic markers.
- To compare treatment-specific responses based on the degree of insulin resistance modulation.
Main Methods:
- A 3-month study involving 212 treatment-naïve T2DM subjects.
- Interventions included a tight Japanese diet (n=65), pioglitazone (15-30 mg/day, n=70), and canagliflozin (50-100 mg/day, n=77).
- Metabolic parameters and changes (Δ) relative to insulin resistance (HOMA-R) were assessed and correlated.
Main Results:
- ΔHOMA-R correlated significantly with ΔFBG and ΔHOMA-B, and negatively with baseline HOMA-R.
- Glycemic and lipid parameters (HbA1c, BMI, TC, TG, non-HDL-C, UA) showed varied responses depending on the treatment regimen.
- Subjects with greater HOMA-R reduction (Group X) had more pronounced FBG reduction across all treatments.
Conclusions:
- Regression to the mean is evident in insulin resistance changes across these T2DM therapies.
- Modulating insulin resistance, whether directly or indirectly, leads to differential impacts on glycemic control, beta-cell function, lipids, and body weight.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Type 2 and Gestational
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:36Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...